Structured population data were available for 3 of 3 supporting studies. 3 studies described participants with type 2 diabetes. 3 studies described adult participants.

1 relevant study has unresolved authoritative design evidence and does not contribute to design-specific or RoB-specific claims.

Evidence uses heterogeneous comparison contexts: active_comparator, usual_care.

2 supporting studies have high, serious, critical, unclear, or unavailable risk-of-bias information.

Sitagliptin 100 mg

Core clinician-reference fields are available or not applicable.

Participants received OW s.c. semaglutide 0.5 mg.

Semaglutide 0.5 mg

Participants were randomised to receive OW s.c. semaglutide 0.5 mg.

Participants received OW s.c. semaglutide 1.0 mg.

Semaglutide 1.0 mg

Participants were randomised to receive OW s.c. semaglutide 1.0 mg.

Participants received OD oral sitagliptin 100 mg.

Participants were randomised to receive OD oral sitagliptin 100 mg.

Once-weekly semaglutide improves glycemic control in Korean adults with T2D

Oral Sitagliptin 100 mg

Participants received once-daily oral semaglutide 3 mg.

Oral Semaglutide 3 mg

Participants were randomised (1:1:1:1) using a web-based randomisation system to either once-daily oral semaglutide (3 mg, 7 mg or 14 mg) or once-daily oral sitagliptin 100 mg.

Participants received once-daily oral semaglutide 7 mg.

Oral Semaglutide 7 mg

Participants received once-daily oral semaglutide 14 mg.

Oral Semaglutide 14 mg

Participants received once-daily oral sitagliptin 100 mg.

Oral semaglutide improves glycemic control in type 2 diabetes

Source evidence could not be resolved sufficiently for this field.

Not extracted from the authoritative source.

Conventional therapy group

Clinician-reference record is usable with limitations in: design, risk_of_bias.

Participants receiving sitagliptin in addition to conventional therapy.

Sitagliptin group

Individuals aged ≥30 y with T2DM (6.2% ≤ HbA1c < 9.4%) were randomly allocated to receive either sitagliptin (25 to 100 mg/d) or conventional therapy.

Participants receiving only conventional therapy (diet, exercise, and/or antidiabetic agents).

Participants were randomly assigned to receive conventional therapy plus sitagliptin (sitagliptin group) or to continue with only conventional therapy.

Authoritative quality diagnostic: sample size arm total mismatch.

Authoritative quality diagnostic: source evidence unresolved.

Sitagliptin shows no additional benefit on carotid thickness in diabetes

Structured population data were available for 3 of 3 supporting studies. 1 study described participants with type 2 diabetes. 3 studies described adult participants.

Structured population data were available for 3 of 3 supporting studies. 2 studies described participants with type 2 diabetes. 3 studies described adult participants.

1 supporting study does not have a displayable topic-matched quantitative effect.

1 study contains conflicting p-value and significance fields; those significance claims are suppressed.

Structured population data were available for 4 of 4 supporting studies. 3 studies described participants with type 2 diabetes. 4 studies described adult participants.

Upstream consistency scoring indicates mixed findings across the evidence.

Structured population data were available for 8 of 8 supporting studies. 4 studies described participants with type 2 diabetes. 8 studies described adult participants.

Evidence uses heterogeneous comparison contexts: baseline_within_group, unknown_unresolved, usual_care.

Evidence uses heterogeneous comparison contexts: baseline_within_group, usual_care.

2 supporting studies do not have a displayable topic-matched quantitative effect.

Evidence uses heterogeneous comparison contexts: active_comparator, unknown_unresolved.

3 supporting studies have high, serious, critical, unclear, or unavailable risk-of-bias information.

Structured population data were available for 4 of 4 supporting studies. 4 studies described participants with type 2 diabetes. 4 studies described adult participants.

Structured population data were available for 5 of 5 supporting studies. Diabetes type was heterogeneous: 2 studies with type 1 diabetes, 1 studies with type 2 diabetes. Age groups were heterogeneous: 2 studies with adult participants, 1 studies with youth participants.

2 relevant studies have unresolved authoritative design evidence and do not contribute to design-specific or RoB-specific claims.

Evidence uses heterogeneous comparison contexts: baseline_within_group, other, usual_care.

4 of 5 studies with duration data have follow-up of 12 weeks or less.

Structured population data were available for 10 of 11 supporting studies. Diabetes type was heterogeneous: 5 studies with type 2 diabetes, 2 studies with type 1 diabetes. 8 studies described adult participants.

3 relevant studies have unresolved authoritative design evidence and do not contribute to design-specific or RoB-specific claims.

3 supporting studies do not have a displayable topic-matched quantitative effect.

Evidence uses heterogeneous comparison contexts: active_comparator, baseline_within_group, placebo, unknown_unresolved, usual_care.

1 supporting study lacks usable structured population information.

4 supporting studies have high, serious, critical, unclear, or unavailable risk-of-bias information.

Structured population data were available for 8 of 8 supporting studies. 7 studies described participants with type 2 diabetes. 7 studies described adult participants.

Evidence uses heterogeneous comparison contexts: active_comparator, baseline_within_group, placebo.

1 supporting study has high, serious, critical, unclear, or unavailable risk-of-bias information.

Structured population data were available for 4 of 4 supporting studies. 4 studies described participants with type 1 diabetes. 2 studies described adult participants.

Structured population data were available for 8 of 8 supporting studies. 6 studies described participants with type 2 diabetes. 7 studies described adult participants.

Evidence uses heterogeneous comparison contexts: active_comparator, unknown_unresolved, usual_care.

Structured population data were available for 8 of 8 supporting studies. Diabetes type was heterogeneous: 4 studies with type 2 diabetes, 1 studies with type 1 diabetes. Age groups were heterogeneous: 4 studies with adult participants, 1 studies with youth participants.

Evidence uses heterogeneous comparison contexts: active_comparator, placebo, usual_care.

5 of 8 studies with duration data have follow-up of 12 weeks or less.

3 of 3 studies with duration data have follow-up of 12 weeks or less.

Evidence uses heterogeneous comparison contexts: active_comparator, placebo.

Evidence uses heterogeneous comparison contexts: active_comparator, baseline_within_group.

Structured population data were available for 3 of 3 supporting studies. Diabetes type was heterogeneous: 1 studies with type 1 diabetes, 1 studies with type 2 diabetes. 2 studies described adult participants.

Structured population data were available for 13 of 13 supporting studies. 11 studies described participants with type 2 diabetes. 12 studies described adult participants.

4 relevant studies have unresolved authoritative design evidence and do not contribute to design-specific or RoB-specific claims.

Evidence uses heterogeneous comparison contexts: active_comparator, baseline_within_group, usual_care.

Evidence uses heterogeneous comparison contexts: unknown_unresolved, usual_care.

Structured population data were available for 3 of 3 supporting studies. Diabetes type was heterogeneous: 2 studies with type 2 diabetes, 1 studies with type 1 diabetes. Age groups were heterogeneous: 2 studies with adult participants, 1 studies with youth participants.

Structured population data were available for 12 of 12 supporting studies. Diabetes type was heterogeneous: 9 studies with type 2 diabetes, 1 studies with type 1 diabetes. 12 studies described adult participants.

9 supporting studies have high, serious, critical, unclear, or unavailable risk-of-bias information.

Structured population data were available for 5 of 5 supporting studies. 5 studies described participants with type 2 diabetes. 4 studies described adult participants.

Structured population data were available for 3 of 3 supporting studies. 2 studies described participants with type 2 diabetes. 2 studies described adult participants.

Structured population data were available for 2 of 3 supporting studies. 2 studies described participants with type 2 diabetes. 2 studies described adult participants.

Evidence uses heterogeneous comparison contexts: active_comparator, placebo, unknown_unresolved.

Structured population data were available for 10 of 10 supporting studies. Diabetes type was heterogeneous: 8 studies with type 2 diabetes, 2 studies with type 1 diabetes. Age groups were heterogeneous: 8 studies with adult participants, 1 studies with youth participants.

Evidence uses heterogeneous comparison contexts: active_comparator, other, usual_care.

3 studies contain conflicting p-value and significance fields; those significance claims are suppressed.

Structured population data were available for 4 of 4 supporting studies. 2 studies described participants with type 2 diabetes. 4 studies described adult participants.

Evidence uses heterogeneous comparison contexts: other, usual_care.

2 of 4 studies with duration data have follow-up of 12 weeks or less.

Structured population data were available for 4 of 4 supporting studies. Diabetes type was heterogeneous: 2 studies with type 2 diabetes, 1 studies with type 1 diabetes. 4 studies described adult participants.

Structured population data were available for 5 of 5 supporting studies. 5 studies described participants with type 2 diabetes. 5 studies described adult participants.

Structured population data were available for 11 of 11 supporting studies. 10 studies described participants with type 2 diabetes. 11 studies described adult participants.

Structured population data were available for 6 of 6 supporting studies. 6 studies described participants with type 2 diabetes. 6 studies described adult participants.

Evidence uses heterogeneous comparison contexts: active_comparator, baseline_within_group, unknown_unresolved, usual_care.

Structured population data were available for 7 of 7 supporting studies. Diabetes type was heterogeneous: 2 studies with type 2 diabetes, 1 studies with type 1 diabetes. 5 studies described adult participants.

Structured population data were available for 5 of 5 supporting studies. 3 studies described participants with type 2 diabetes. 4 studies described adult participants.

Structured population data were available for 5 of 5 supporting studies. Diabetes type was heterogeneous: 4 studies with type 2 diabetes, 1 studies with type 1 diabetes. 3 studies described adult participants.

Evidence uses heterogeneous comparison contexts: baseline_within_group, placebo, usual_care.

Sitagliptin × HbA1c

Available supporting studies

Once-weekly semaglutide improves glycemic control in Korean adults with T2D

Oral semaglutide improves glycemic control in type 2 diabetes

Sitagliptin shows no additional benefit on carotid thickness in diabetes